Altamira Therapeutics CYTO Stock
Altamira Therapeutics Price Chart
Altamira Therapeutics CYTO Financial and Trading Overview
| Altamira Therapeutics stock price | 1.83 USD |
| Previous Close | 0.81 USD |
| Open | 0.87 USD |
| Bid | 0 USD x 1400 |
| Ask | 0 USD x 800 |
| Day's Range | 0.79 - 0.87 USD |
| 52 Week Range | 0.69 - 15 USD |
| Volume | 1.51M USD |
| Avg. Volume | 2.38M USD |
| Market Cap | 5.8M USD |
| Beta (5Y Monthly) | 1.28169 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -433.43 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
CYTO Valuation Measures
| Enterprise Value | 11.64M USD |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 18.980911 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 38.092 |
| Enterprise Value/EBITDA | -0.85 |
Trading Information
Altamira Therapeutics Stock Price History
| Beta (5Y Monthly) | 1.28169 |
| 52-Week Change | -92.96% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 15 USD |
| 52 Week Low | 0.69 USD |
| 50-Day Moving Average | 1.03 USD |
| 200-Day Moving Average | 3.77 USD |
CYTO Share Statistics
| Avg. Volume (3 month) | 2.38M USD |
| Avg. Daily Volume (10-Days) | 446.81K USD |
| Shares Outstanding | 6.99M |
| Float | 6.89M |
| Short Ratio | 0.08 |
| % Held by Insiders | 7.10% |
| % Held by Institutions | 0.61% |
| Shares Short | 206.58K |
| Short % of Float | 2.95% |
| Short % of Shares Outstanding | 2.95% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:20 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -4494.31% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -67.40% |
| Return on Equity (ttm) | -1123.74% |
Income Statement
| Revenue (ttm) | 305.62K USD |
| Revenue Per Share (ttm) | 0.34 USD |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -13688696 USD |
| Net Income Avi to Common (ttm) | -26528412 USD |
| Diluted EPS (ttm) | -31.61 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 15.4K USD |
| Total Cash Per Share (mrq) | 0.002 USD |
| Total Debt (mrq) | 6.33M USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 0.137 |
| Book Value Per Share (mrq) | -7.046 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -8683231 USD |
| Levered Free Cash Flow (ttm) | -7332829 USD |
Profile of Altamira Therapeutics
| Country | United States |
| State | N/A |
| City | Hamilton |
| Address | Clarendon House |
| ZIP | HM 11 |
| Phone | 441-295-5950 |
| Website | https://altamiratherapeutics.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 16 |
Altamira Therapeutics Ltd., a clinical-and commercial-stage biopharmaceutical company, engages in the development of therapeutics that address various unmet medical needs in Switzerland, the United States, Europe, and Australia. The company develops OligoPhore/SemaPhore, a platform for delivery of oligonucleotides, such as small interfering ribonucleic acid or messenger RNA into target cells. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also developing AM-401 for the treatment of KRAS driven cancer; AM-411 for the treatment of rheumatoid arthritis; AM-125 that is in phase II clinical trial for the treatment of vertigo; Keyzilen, which is in phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. The company was founded in 2003 and is headquartered in Hamilton, Bermuda.
Q&A For Altamira Therapeutics Stock
What is a current CYTO stock price?
Altamira Therapeutics CYTO stock price today per share is 1.83 USD.
How to purchase Altamira Therapeutics stock?
You can buy CYTO shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Altamira Therapeutics?
The stock symbol or ticker of Altamira Therapeutics is CYTO.
Which industry does the Altamira Therapeutics company belong to?
The Altamira Therapeutics industry is Biotechnology.
How many shares does Altamira Therapeutics have in circulation?
The max supply of Altamira Therapeutics shares is 2.24M.
What is Altamira Therapeutics Price to Earnings Ratio (PE Ratio)?
Altamira Therapeutics PE Ratio is now.
What was Altamira Therapeutics earnings per share over the trailing 12 months (TTM)?
Altamira Therapeutics EPS is -433.43 USD over the trailing 12 months.
Which sector does the Altamira Therapeutics company belong to?
The Altamira Therapeutics sector is Healthcare.
Altamira Therapeutics CYTO included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
- {{ link.label }} {{link}}